Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL patients, offering treatment-free intervals. Safety profiles differed, with ...
Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
Fixed-duration regimens of venetoclax combined with obinutuzumab (VO) or ibrutinib (VI) show efficacy similar to that of continuous ibrutinib monotherapy in the first-line treatment of chronic ...
In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...
Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...
Please provide your email address to receive an email when new articles are posted on . Pirtobrutinib significantly improved PFS for patients with CLL and SLL compared with standard chemoimmunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback